A Clinical Trial of COVAC-2 in Adults

Severe Acute Respiratory Syndrome Coronavirus 2 Clinical Trial

Official title: A Randomized, Observer-Blind, Dose-Escalation Phase 2 Clinical Trial of COVAC-2 in Generally Healthy Adults

Status Completed

Clinical Trial Summary

VIDO has developed a vaccine called COVAC-2.

The COVAC-2 study vaccine contains a portion of the SARS-CoV-2 spike protein, called S1. The spike protein is the part of the virus that is responsible for attaching to the surface of host cells. COVAC-2 contains a SWE adjuvant. An adjuvant is a compound that is added to a vaccine to help the vaccine produce a better immune response. The SWE adjuvant is similar to another adjuvant, MF59, that is found in influenza vaccines and MF59 containing vaccines have been given to millions of people around the world. The vaccine is expected to stimulate the body to make antibodies against the S1 protein. The antibodies will recognize the viral spike protein if the body is exposed to the virus and prevent severe COVID-19 illness. In animal studies, the immune response generated by the COVAC-2 vaccine was able to protect the vaccinated animals against a severe SARS-CoV-2 infection.

This is a Phase 2, placebo-controlled, observer-blind, age-stratified randomized, multicentre study to test the safety and immunogenicity of a dose level of the COVAC-2 vaccine (25 µg protein) administered twice (4 weeks apart) in generally healthy adults 18+ years of age. Up to 300 participants will be enrolled. For an individual participant, the duration of study will be approximately 12 months from the first vaccination (Day 0).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Severe Acute Respiratory Syndrome
• Severe Acute Respiratory Syndrome Coronavirus 2

• NCT number: NCT05209009
• Study type: Interventional
• Source: University of Saskatchewan
• Status: Completed
• Phase: Phase 2
• Start date: August 24, 2022
• Completion date: March 1, 2024